Why the CSL Limited share price is looking up

CSL Limited (ASX:CSL) is up 45% over the last 12 months on the back of excellent earnings growth and potential.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares in biotechnology company CSL Limited (ASX: CSL) hit a new record high of $145.62 in Thursday's trading session despite no announcement being released to the market.

CSL shares have soared 45% over the past 12 months after the Melbourne-based company continues to deliver excellent profit growth on the back of strong demand for its immunoglobulin and specialty products in conjunction with rising margins.

The company's shares have now risen 14% after announcing its FY 17 numbers in mid August where it posted a net profit of $US1,337 million on a constant currency basis – a 24% improvement on 2016.

Future growth

CSL is not resting on its laurels either, with the company cancelling its successful share buyback program to redistribute its free cash flow towards an extensive capex program of between $US900 million and $US1 billion in FY 2018.

The capex program is geared towards enhancing the company's growth prospects with substantial investments being planned to expand its fractionation capacity, increase the number of collection centres and boost manufacturing capacity for specialty products such as Haegarda and Berinert.

The acquisition of Chinese plasma fractionator Ruide should also contribute strongly to future earnings with the Chinese immunoglobulin market the fastest growing market in the world and a shortage predicted to occur over the next decade.

The influenza vaccine division Seqirus is also seeing revenue growth and is on the path to profitability.

Foolish takeaway

CSL remains one of the best Australian companies to profit from a depreciating Australian dollar with a considerable amount of its revenue derived in US dollars around the world.

The stock continues to be the star of the Australian healthcare sector and whilst far from cheap offers a more compelling valuation than fellow healthcare heavyweight Cochlear Limited (ASX: COH).

CSL has guided for FY 2018 net profit to rise between 11% to 16% at constant currency and trades at approximately 32x forward earnings. In contrast, Cochlear has guided for net profit to grow between 7% to 12% and trades at about 41 times forward earnings.

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »